

# CCL1 blockade alleviates human mesenchymal stem cell (hMSC)-induced pulmonary fibrosis in a murine sclerodermatous graft-versus-host disease (Scl-GVHD) model

**Ji-Young Lim**

Catholic University of Korea

**Da-Bin Ryu**

Catholic University of Korea School of Medicine

**Tae Woo Kim**

The Catholic University of Korea

**Sung-Eun Lee**

Seoul St. Mary's Hospital, The Catholic University of Korea

**Gyeongsin Park**

Seoul St. Mary's Hospital, The Catholic University of Korea

**Hyoung Kyu Yoon**

St. Mary's Hospital, The Catholic University of Korea

**Chang-Ki Min** (✉ [ckmin@catholic.ac.kr](mailto:ckmin@catholic.ac.kr))

Seoul Saint Mary's Hospital, The Catholic University of Korea

---

## Research

**Keywords:** mesenchymal stem cells, chronic graft-versus-host disease, sclerodermatous graft-versus-host disease, allogeneic hematopoietic stem cell transplantation

**Posted Date:** March 30th, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-19594/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published on June 26th, 2020. See the published version at <https://doi.org/10.1186/s13287-020-01768-7>.

# Abstract

## Background

Human chronic graft-versus-host disease (CGVHD) shares clinical characteristics with a murine sclerodermatous GVHD (Scl-GVHD, B10.D2 → BALB/c) model that is characterized by skin and lung fibrosis. In this study, bone marrow- or adipose tissue-derived human mesenchymal stem cells (hMSCs) were injected into the Scl-GVHD mice to address their therapeutic effect on CGVHD.

## Methods

Lethally irradiated BALB/c mice were transplanted with B10.D2 T cell depleted bone marrow with or without spleen cells to generate Scl GVHD. hMSCs were intravenously treated on days 3, 5 and 7 post-transplantation. And the control antibody or CCL1 blocking antibody was subcutaneously injected into the same schedule as hMSCs. At 14 days after transplantation, the recipient mice sacrificed and their skin and lung analyzed.

## Results

After early injection of hMSCs after transplantation, the clinical and pathological severity of Scl-GVHD in the skin was significantly attenuated, whereas the pathological score was exacerbated in the lungs. hMSCs migrated into the lungs but not into the skin. CD11b monocyte/macrophages and CD4 T cells were markedly decreased in skin tissues, whereas there was an early recruitment of CD11b cells, and subsequently increased infiltration of CD4 T cells, in the lungs. Importantly, hMSCs persistently up-regulated the expression of CCL1 in the lungs but not in the skin. Concurrent treatment of hMSCs with a CCL1-blocking antibody alleviated the severity of the lung histopathology score and fibrosis with preservation of the cutaneous protective effect against CGVHD. Infiltration of CD3 T cells and CD68 macrophages and up-regulation of chemokines were also decreased in lung tissues, along with recruitment of eosinophils and tissue IgE expression. In the skin, chemokine expression was further reduced after CCL1 blockade.

## Conclusions

These data demonstrate that despite a protective effect against Scl-GVHD in the skin, administration of hMSCs exacerbated lung fibrosis associated with eosinophilia and airway inflammation through persistent CCL1 up-regulation. CCL1 blockade offers a potential treatment of pulmonary complications induced after treatment with hMSCs.

## Background

The prevalence and severity of chronic graft-versus-host disease (CGVHD) are believed to have risen over the past two decades in association with the increasing use of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in older patients, the widespread use of mobilized blood cells instead of

marrow for grafting, and improvements in survival during the first several months after allo-HSCT [1, 2]. Currently available therapies using long-term immunosuppressive treatments have demonstrated limited efficacy. Sclerodermatous GVHD (Scl-GVHD), the most common pathological change in human CGVHD, affects almost all organs and tissues and is manifested by a marked increase in collagen deposition. The main clinical manifestations of Scl-GVHD include lichenoid lesions, sclerodermatous lesions, disorders of pigmentation (e.g., areas of hypopigmentation and hyperpigmentation), and leopard-skin eruptions (widespread, well-delimited, hyperpigmented macules) [3, 4, 5]. Very few experimental models exist to examine CGVHD [6]. Among them, the B10.D2 (H-2<sup>d</sup>) → BALB/c (H-2<sup>d</sup>), major histocompatibility complex (MHC)-matched and minor histocompatibility antigen-mismatched model replicates human Scl-GVHD and systemic sclerosis, predominantly with the thickening of skin and pulmonary fibrosis following increased collagen and excessive extracellular matrix deposition [7, 8, 9].

Mesenchymal stem cells (MSCs) are stromal cells that normally reside within the adult bone marrow and can differentiate into many adult cell types such as osteocytes, chondrocytes and adipocytes [10]. We previously reported that allogeneic murine MSCs (mMSCs) attenuate cutaneous Scl-GVHD by selectively blocking immune cell migration and downregulating chemokines and chemokine receptors in the murine Scl-GVHD model [11]. To improve clinical applicability, we chose to study human MSCs (hMSCs), given the multiple differences in immunomodulatory effects between the two MSCs. hMSCs possess immunomodulatory properties in addition to producing soluble proteins that critically support hematopoietic stem cell homeostasis and engraftment [12, 13, 14]. Given their immunosuppressive properties, ease in expansion, and safe infusion profile [15], hMSCs have been clinically used for steroid-refractory acute GVHD [16]. Yet the protection against Scl-GVHD, bio-distribution and mechanisms underlying *in vivo* hMSC effects remain largely undefined. Murine xenogeneic transplant models could be useful in defining *in vivo* hMSC-mediated immunosuppression, since hMSCs have low immunogenicity, lack MHC class II and co-stimulatory molecule expression, and fail to activate T-cells *in vitro* [17]. We tested the hypothesis that hMSCs would attenuate the severity of Scl-GVHD in mice after allo-HSCT. hMSCs attenuated Scl-GVHD in the skin but localized to injured lungs, worsening pulmonary fibrosis. hMSCs elicited immune cell migration caused by up-regulation of CCL1, which contributed to a fibrotic response in lung. We found that hMSCs exerted a paradoxically different effect between skin and lung tissues in an established Scl-GVHD model, offering a possible treatment strategy to improve the severity of cutaneous Scl-GVHD while reducing pulmonary complications.

## Methods

### Experimental allo-HSCT and MSCs

Female B10.D2 (H-2<sup>d</sup>) and BALB/c (H-2<sup>d</sup>) mice (8 to 12 weeks old) were purchased from Shizuoka Institute for Laboratory Animals (Japan SLC, Shizuoka, Japan). Briefly, recipient (BALB/c) mice were lethally irradiated with 650 cGy using a Gammacel<sup>137</sup>Cs source. Approximately 6 h later they were injected *i.v.* via the tail vein with donor (B10.D2) T cell-depleted bone marrow (5 x 10<sup>6</sup> cells/mouse) and

spleen cells ( $3 \times 10^6$  cells/mouse) (referred to as Scl-GVHD mice). A control group of BALB/c recipient mice received either B10.D2 donor BM without T cells (non-GVHD controls) or BALB/c BM with T cells (syngeneic controls). The primary human BM and AD MSCs were obtained from a stem cell bank. BM-MSCs (Scl-GVHD + hBM-MSCs) or AD-MSCs (Scl-GVHD + hAD-MSCs) were administered after allo-HSCT at a dose of  $3 \times 10^5$  cells/mouse.

### **GVHD skin score and histopathological analysis**

The clinical skin GVHD score was modified as previously described [7]. The minimum score was 0, and the maximum score was 8. Formalin-fixed, paraffin-embedded tissue sections were subjected to hematoxylin-eosin (H&E)-staining for microscopic examination and Masson's trichrome staining for fibrosis. Slides were scored by a pathologist (blinded to experimental groups). Dermal thickening from the bottom of the epidermis to the fat was evaluated for each animal as previously described [18]. Collagen deposition was quantified on trichrome stained sections as the ratio of blue-stained area to total stained area using digital analyzer software ImageJ (<http://rsb.info.nih.gov>).

### **Protein extracts and measurement of soluble collagen**

Tissue samples were homogenized in 2 ml of buffer solution and centrifuged at 3,000 rpm for 20 min, after which supernatants were harvested. Total protein concentrations in supernatant were determined using the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA). Total soluble collagen was quantified using the Sircol Soluble Collagen Assay (Bio-color, Belfast, Ireland) as previously described [19].

### **Immunohistochemical (IHC) staining**

Tissue sections (4  $\mu$ m) were mounted on super frost glass slides and deparaffinized in xylene and a graded series of ethanol, followed by antigen retrieval. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide. Nonspecific binding sites were saturated by exposure to 10% normal goat serum diluted in PBS for 60 min. Slides were then incubated overnight at 4°C with primary antibodies against mouse MMP1 (1:250 dilution, Abcam), PTEN (1:100 dilution, Abcam), pSmad3 (1:200 dilution, Invitrogen), CD3 (1:400 dilution, Santa Cruz), CD68 (1:250 dilution, Abcam) or EPX (1:200 dilution, Abcam), then washed with PBS for 10 min. Biotinylated goat anti-rabbit IgG and rabbit anti-goat IgG (Vector Laboratories, Burlingame, CA) secondary antibodies were applied to tissue sections, and the slides were incubated at room temperature for 30 min. After the sections were washed and incubated for 30 minutes with peroxidase-conjugated streptavidin (Dako, Glostrup, Denmark) at room temperature, 3,3'-diaminobenzidine was added to visualize antigens. Sections were counterstained with Mayer's hematoxylin, dehydrated, cleared, and mounted. Negative control tissue samples were prepared in the same manner as described above, except that the primary antibody was omitted or replaced with an isotype control antibody (R&D Systems, Minneapolis, MN).

IHC stains were evaluated for the presence of positively staining cells in the dermis as previously described [20]. In brief, the following semiquantitative scale, based on the percentage of positive cells,

was used: 0 (no staining), 1 (<25% staining), 2 (25–50% staining), 3 (50–75% staining), or 4 (75–100% staining). Stained cells were counted under a high-power microscopic field (400 X original magnification) on a light microscope.

### **Fluorescent detection for *in vivo* tracking of MSCs**

Primary hMSCs were labeled with PKH-26 according to the manufacturer's instructions (Sigma-Aldrich, St. Louis, Mo, USA) and injected into recipient mice. To evaluate MSC recruitment, tissues were immediately embedded in OCT (CellPath) embedding matrix, placed on dry ice and stored at -80°C. Tissues were then sectioned on a cryostat (4 μ), fixed with acetone, and, after washing, stained with 4,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich). Slides were examined using a confocal microscope (LSM700; Carl Zeiss).

### **Quantitative real-time (qRT)-PCR analysis**

Total RNA was isolated from skin and lung homogenates with Trizol (Invitrogen, Carlsbad, USA) in accordance with the manufacturer's instructions. The quantity of mRNA was calculated using the  $2^{-\Delta\Delta Ct}$  method, and  $\beta$ -actin was used to normalize total RNA quantities.

### **Bronchoalveolar lavage (BAL)**

BAL was performed in situ four times with Hanks' balanced salt solution (35 mL/kg; pH 7.2–7.4, WelGENE Inc.). Cell pellets were resuspended in 1 ml of HBSS, and then counted using a hemocytometer.

### **Cell isolation and flow cytometric analysis**

Mononuclear cells were isolated from skin as previously described [18]. Briefly, minced skin was digested for 30 min in complete medium supplemented with Liberase and DNase (both purchased from Roche), and leukocytes were isolated by density gradient centrifugation on Accuprep medium (Accurate Chemical, Oslo, Norway). To determine the surface phenotype, cells were stained with PE-conjugated anti-CD11b and APC-Cy7-conjugated anti-CD4.

### **Measurements of IgE by ELISA**

Concentrations of IgE in the supernatants of homogenized tissues were measured by ELISA (Biolegend).

### **Statistical analysis**

All values are expressed as mean  $\pm$  standard error of the mean (SEM). Statistical comparisons between groups were performed using a parametric independent sample t-test if there were  $\geq 5$  animals per group, or using the Mann-Whitney test if there were <5 animals per group.

## **Results**

## Characteristics of hMSCs

hMSCs are characterized by expression of several surface markers and display multipotent differentiation along mesenchymal lineages. The hMSCs expanded in culture showed positive surface staining for CD44, CD73 and CD166, but lacked CD34, CD45, CD14, CD11b and HLA-DR surface expression (Supplementary Figure 1a). hMSCs were routinely frozen in medium containing 10% dimethyl sulfoxide (DMSO) in 90% FBS, and retained the capacity to differentiate into adipogenic, osteogenic, and chondrogenic lineages (Supplementary Figure 1b).

## Early injection of hMSCs attenuated the severity of murine Scl-GVHD in the skin but exacerbated pulmonary inflammation and fibrosis

Bone marrow (BM)- or adipose tissue (AD)-derived hMSCs were intravenously administered to allogeneic recipients on days 3, 5 and 7 after experimental allo-HSCT. The clinical severity of Scl-GVHD in the skin was significantly attenuated in hBM or hAD MSC-treated recipients relative to Scl-GVHD controls (Figure 1a). Histologic examination revealed thickening of the epithelial layer, loss of hair follicles and subdermal fat, and ulcers in the epithelial and dermal layers in skin lesions of Scl-GVHD controls. The pathological severity of Scl-GVHD in the skin but not the lungs was significantly attenuated in either hBM or hAD MSC-treated recipients relative to Scl-GVHD controls at days 14 and 28 (Figure 1b).

Moreover, in both BM and AD hMSC-treated groups, fibrosis areas and collagen amounts in the skin but not in the lungs were significantly lower than those in the allogeneic control group (Figure 1c). In parallel, the mRNA expression levels of collagen type 1  $\alpha$ 1 (*COL1A1*), 1  $\alpha$ 2 (*COL1A2*) and 3  $\alpha$ 1 (*COL3A1*) were significantly reduced in skin tissue after both hBM and hAD MSC treatment, compared to those in allogeneic Scl-GVHD controls. In contrast, those parameters were largely increased in lung tissue after both hBM and hAD MSC treatment (Figure 1d). Type I collagen, the most abundant extracellular matrix (ECM) protein, is deposited excessively in the dermis of scleroderma. Matrix metalloproteinases (MMPs) play a major role in ECM degradation [21]. In injured human skin, MMP-1 is induced as wound-edge keratinocytes bind type I collagen in the dermis, and the ability of this proteinase to cleave collagen is key to facilitating keratinocyte movement [22]. MMP-1 expression in the skin was reduced in hMSC-treated allogeneic recipients compared with Scl-GVHD controls. However, expression of MMP-1 was significantly increased in lung tissue after hMSC treatment (Figure 1e). TGF- $\beta$  plays a central role in pathological tissue fibrosis. TGF- $\beta$  triggers the activation of numerous signaling pathways, which contribute to progressive fibrosis, including the Smad pathway [23]. TGF- $\beta$  suppresses PTEN expression, and inhibition of PTEN activity is necessary for TGF- $\beta$ -induced expression [24]. hBM and hAD MSC treatment restored PTEN expression and reduced the level of Smad-3 phosphorylation in the skin (Figure 1f and 1g, respectively). In the lung, however, the levels of PTEN did not differ between hMSC-treated allogeneic recipients and Scl-GVHD controls, and Smad-2/3 phosphorylation was increased in BM and AD hMSC-treated allogeneic recipients (Figure 1f and 1g, respectively).

## *In vivo* detection of injected hMSCs in each organ and infiltration of immune effector cells into the skin and lungs

To examine the life-span of hMSCs in GVHD target organs and secondary lymphoid organs, allogeneic recipients receiving AD-hMSCs were sacrificed at 7, 14, 21, 28 and 35 days after allo-HSCT. hMSCs were frequently observed in the lungs, liver, spleen and peripheral lymph nodes (LN), but not the skin (Figure 2a). It has been noted that initial target organ inflammation is caused primarily by CD11b monocytes and T cells (Hamilton BL et al., 1087). We performed flow cytometric analysis of skin cell suspensions and BAL fluid using CD4 and CD11b surface markers. The frequency of CD4 T (Figure 2b) and CD11b cells (Figure 2c) was markedly increased in skin cells and BAL fluid following allo-HSCT. After BM- and AD-hMSC treatment, the frequencies of CD4 T and CD11b cells in the skin were markedly decreased compared to those in Scl-GVHD controls. On the other hand, there was an early accumulation of CD11b cells followed by the increase in infiltrating CD4 T cells thereafter. Leucocyte proportion in BAL fluid was enumerated by cytopspin, and eosinophils were significantly increased after treatment with hMSCs in Scl-GVHD mice (Figure 2d).

### **Injection of hMSCs elicited differential expression of chemokines between the skin and lungs**

Chemokines play important roles in recruiting cells of the innate and adaptive immune system to sites of inflammation. Several studies have now described increased expression of chemokine receptors in GVHD [25]. The profile of chemokines and their receptor expression differs according to the target organs [26]. In the skin and lungs, mRNA for chemokines CCL1, CCL2, CCL3, CCL5, CCL8, CCL17 and CCL22 was upregulated in Scl-GVHD controls. As shown in figure 3a, chemokine mRNA expression was significantly reduced by hMSCs in the skin, however hMSCs up-regulated the expression of Th2 chemokines such as CCL1, CCL17 and CCL22 in the lungs. Among them, enhanced CCL1 mRNA expression in the lungs was maintained up to 28 days after transplantation. CCL1 is the only known ligand for CCR8, whereas CCL22 and CCL17 both interact with CCR4 [27]. In the lungs, mRNA expression of CCR4, CCL17 and CCL22 receptor and CCR8, CCL1 receptor was also significantly increased after hMSC treatment (Figure 3b).

### **Concurrent treatment with hMSCs and CCL1-blocking antibody alleviated the severity of lung histopathology score and fibrosis with preservation of the CGVHD protective effect in the skin**

To further investigate whether CCL1 plays a role in the pathogenesis of pulmonary inflammation induced by hMSCs, we evaluated whether neutralization of CCL1 attenuated pulmonary inflammation without affecting the skin. Treatment with CCL1-neutralizing Abs reduced the severity of the lung pathological score while maintaining the protective effect against Scl-GVHD in the skin (Figure 4a). Moreover, treatment with CCL1-blocking Ab also reduced pulmonary fibrosis induced by hMSCs (Figure 4b) as compared with control Ab-treated mice. Next, we investigated whether CCL1 blockade could mitigate infiltration of effector cells in target organs. CCL1 blockade reduced the infiltration of CD3 T cells and CD68 macrophage in lung tissues (Figure 4c).

### **CCL1 blockade reduced chemokine expression linked to airway infiltration of Th2-based CD4 T cells as well as eosinophil infiltration**

Th2 cells have been identified as the cells involved in controlling immunoglobulin E (IgE) production and influencing the functions of eosinophils [28]. We investigated whether CCL1 blockade could reduce Th2 chemokine expression and eosinophil infiltration induced by hMSCs. Up-regulated chemokines such as CCL1, CCL17 and CCL22 were also decreased after anti-CCL1 treatment in lung tissues. Moreover, expression of CCL1 and CCL17 in the skin was further reduced after concomitant administration of hMSCs and anti-CCL1 compared to hMSCs alone (Figure 5a). Next, we analyzed eosinophil infiltration after CCL1 blockade using eosinophil peroxidase (EPX) staining in target tissues. EPX is a major constituent of the large cytoplasmic granules of eosinophilic leukocytes. Treatment with CCL1-blocking Ab reduced eosinophil infiltration in the lungs compared to control Ab-treated mice (Figure 5b). In parallel, CCL1 blockade also reduced hMSC-induced IgE production in lung tissues (Figure 5c).

## Discussion

*Ex vivo*-expanded MSCs derived from various tissue sources can be used in both autologous and allogeneic settings for the evaluation of therapeutic efficacy. Multiple clinical studies have confirmed the safety of both allogeneic and autologous MSCs for the treatment of various human diseases [15]. The immune evasive and immunomodulatory properties of MSCs allow them to avoid immunologic rejection in an unrelated recipient and render them suitable for allogeneic or even xenogeneic cell therapy [29, 30]. Therefore, comprehensive preclinical safety and toxicity studies are needed before administering these cells into humans. In particular, the use of hMSCs to prevent or treat CGVHD with sclerodermatous changes has been limited by an incomplete understanding of the mechanism of action of these cells and unverified risks. In this study, we showed that administration of AD- or BM-derived hMSCs early after experimental allo-HSCT clearly reduced the severity of cutaneous GVHD of allogeneic recipients, as determined by both skin manifestation and histopathology. Yet hMSCs also markedly exacerbated the inflammation and fibrosis in the lungs of Scl-GVHD mice. hMSCs specifically decreased the infiltration of both CD4 T and CD11b effector cells into the skin, but led to an increase in CD11b cells, particularly eosinophils, infiltrating into the lungs, followed by CD4 T cells. Expression of chemokines and chemokine receptors was different between the two organs, and we reasoned that continuous up-regulation of CCL1 in the lungs induced by hMSCs could be related to pulmonary fibrosis with eosinophilia and airway inflammation. Concurrent treatment of hMSCs with a CCL1-blocking antibody reduced the effector cell infiltration and improved lung injury without attenuation of the protective effect against CGVHD on the skin. These results suggest that CCL1 blockade may be a potential treatment of pulmonary complications induced after hMSC treatment in clinics.

In this murine Scl-GVHD model [31], infiltration of mononuclear cells (predominantly CD4 T cells and CD11b monocyte/macrophages) into target organs starts 14 days after allo-HSCT [8, 11, 32]. After injection of hMSCs, the infiltration of mononuclear cells was profoundly reduced into the skin, whereas in the lung an increase in infiltrating CD4 T cells followed after early accumulation of CD11b cells. The entry of leukocytes into lymphoid and nonlymphoid tissues is controlled by sequential engagement of inflammatory cytokines and/or chemokines [33, 34]. It has been previously shown that mMSCs attenuate cutaneous Scl-GVHD by selectively blocking immune cell migration and down-regulating chemokines and

chemokine receptors [11]. We wondered whether chemokine expression pattern was a factor determining the preferential organ involvement after early injection of hMSCs, which led us to analyze chemokine receptors involved in lung diseases [35]. After hMSC infusion, elevated expression of skin profibrotic chemokines such as CCL1, CCL2, CCL3, CCL8, CCL17, and CCL22 were down-regulated, consequently resulting in decreased infiltration of immune cells into skin tissues. In contrast, hMSCs enhanced the expression of CCL1 with CCR8, CCL17 and CCL22 with CCR4 in the lungs, contributing to the early recruitment of CD11b cells, particularly eosinophils, to the lung. CCL1 binds exclusively to CCR8, whereas CCL22 and CCL17 both interact with CCR4 [27]. We found that hMSCs early after transplantation allowed eosinophils to be recruited into the lungs, which played a major role in pulmonary inflammation and fibrosis. Neutralizing either CCL22 or CCL17 has been shown to abrogate lung eosinophilia and airway hyperresponsiveness [36, 37]. Direct instillation of CCL1 into the lungs of allergen-sensitized challenged mice induces the recruitment of eosinophils and CCL1 blockade induces a modest reduction in eosinophil recruitment [38]. In our study, CCL1 blockade had a beneficial effect on hMSC-induced pulmonary complications by suppressing the infiltration of CD3 and CD68 cells into the lungs. Despite available *in vitro* and *in vivo* data suggesting that chemokine blockade may have a beneficial effect on airway hypersensitivity and asthma, to the best of our knowledge, there have been no studies that have found whether CCL1 blockade is involved in regulating the severity of pulmonary fibrosis in CGVHD models. Notably, we saw that CCL1 blockade with hMSCs resulted in a decrease in enhanced expression of CCL1, CCL17 and CCL22 induced by hMSCs in both the lungs and skin, indicating that CCL1 likely plays a critical role in recruitment of immune effector cells into the lung after administration of hMSCs. In particular, eosinophil trafficking and elevated IgE concentration in the lungs after hMSC treatment were also decreased by CCL1 blockade.

The current study did not evaluate the mechanistic basis by which the CCR8-CCL1 axis controlled and coordinated the paradoxical influx of inflammatory cells between the lungs and skin after hMSC injection. CCR8, the CCL1 receptor, is known to be critical for regulatory T (Treg) function. In mice, the chemokine receptor CCR8 is expressed principally on Treg cells and also notably on small fractions of Th2 cells, monocytic cells, and NK cells [39, 40, 41]. A similar expression pattern is seen in humans, in which CCR8 expression identifies CD4 memory T cells enriched for Foxp3<sup>+</sup> regulatory and Th2 effector lymphocytes [42]. CCL1 may also have multiple effects on Treg and T effector biology. Therefore, blocking its activity may also have multiple end points. Moreover, while the combination of hMSCs with CCL1 blockade in an experimental CGVHD model provides preliminary data supporting further exploration, it is too early to see the effects of this work clinically translated.

## Conclusion

In this study we showed that administration of hMSCs in a xenogenic murine Scl-GVHD model effectively attenuated the severity of skin fibrosis but paradoxically exacerbated pulmonary inflammation and fibrosis. CCL1 was identified to be a main contributing factor for MSC-induced recruitment of immune effector cells into the lungs. Concurrent treatment with hMSCs and a CCL1-blocking agent alleviated lung

injury caused by hMSCs without detrimental effects on cutaneous CGVHD protection. We propose that neutralization of CCL1 offers a potential means of preventing pulmonary complications induced by hMSCs when patients with Scl-GVHD or scleroderma are treated with hMSCs in clinic.

## Abbreviations

BAL: Bronchoalveolar lavage

BM: Bone marrow

ECM: Extracellular matrix

ELISA: Enzyme-linked immunosorbent assay

EPX: Eosinophil peroxidase

GVHD: Graft versus host disease

HSCT: Hematopoietic stem cell transplantation

LN: Lymph node

MHC: Major histocompatibility complex

MMP: Matrix metalloproteinase

MSC: Mesenchymal stem cell

PTEN: Phosphatase and tensin homolog

SCL: Scleroderma

TGF- $\beta$ : Transforming Growth Factor-beta

## Declarations

### **Ethics approval and consent to participate**

Institutional Animal Care and Use Committee (IACUC) and Department of Laboratory Animal (DOLA) in Catholic University of Korea, Songeui Campus accredited the Korea Excellence Animal laboratory Facility from Korea Food and Drug Administration in 2017 and acquired AAALAC International full accreditation in 2018. All procedures involving animals were in accordance with the Laboratory Animals Welfare Act, the Guide for the Care and Use of Laboratory Animals, and the Guidelines and Policies for Rodent Experimentation provided by the Institutional Animal Care and Use Committee of the School of Medicine

of The Catholic University of Korea. The study protocol was approved by the Institutional Review Board of The Catholic University of Korea (CUMC-2016-0062-03).

### **Consent for publication**

Not applicable

### **Availability of data and materials**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

### **Competing interest**

The authors have no conflicts of interest to declare.

### **Funding**

This research was supported by a grant (14172MFDS974) from the Ministry of Food and Drug Safety in 2016.

### **Author's contributions**

J-YL: conception and design, collection and/or assembly of data, data analysis and interpretation, manuscript writing; D-BR: data analysis and interpretation, performed laboratory work; TWK: performed laboratory work; S-EL: data analysis and interpretation; GP: data analysis and interpretation; HGY: data analysis and interpretation; C-KM: financial support, conception and design, data analysis and interpretation, manuscript writing, final approval of the manuscript.

### **Acknowledgements**

This study was supported by the Ministry of Food and Drug Safety, Korea. The authors thank the staff of CENST, whose work was excellent for the integrity of the work as a whole.

## **References**


1. Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. *Blood*. 2015;125:606-15.
2. Flowers ME, Parker PM, Johnston LJ, Matos AV, Storer B, Bensinger WI, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. *Blood*. 2002;100:415-9.
3. Cho BS, Min CK, Eom KS, Kim YJ, Kim HJ, Lee S, et al. Feasibility of NIH consensus criteria for chronic graft-versus-host disease. *Leukemia*. 2009;23:78-84.
4. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I.

- Diagnosis and staging working group report. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 2005;11:945-56.
5. Penas PF, Jones-Caballero M, Aragues M, Fernandez-Herrera J, Fraga J, Garcia-Diez A. Sclerodermatous graft-vs-host disease: clinical and pathological study of 17 patients. *Archives of dermatology*. 2002;138:924-34.
  6. Schroeder MA, DiPersio JF. Mouse models of graft-versus-host disease: advances and limitations. *Disease models & mechanisms*. 2011;4:318-33.
  7. Anderson BE, McNiff J, Yan J, Doyle H, Mamula M, Shlomchik MJ, et al. Memory CD4+ T cells do not induce graft-versus-host disease. *The Journal of clinical investigation*. 2003;112:101-8.
  8. McCormick LL, Zhang Y, Tootell E, Gilliam AC. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. *Journal of immunology (Baltimore, Md : 1950)*. 1999;163:5693-9.
  9. Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. *Journal of immunology (Baltimore, Md : 1950)*. 2002;168:3088-98.
  10. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy*. 2006;8:315-7.
  11. Lim JY, Ryu DB, Lee SE, Park G, Min CK. Mesenchymal Stem Cells (MSCs) Attenuate Cutaneous Sclerodermatous Graft-Versus-Host Disease (Scl-GVHD) through Inhibition of Immune Cell Infiltration in a Mouse Model. *The Journal of investigative dermatology*. 2017;137:1895-904.
  12. English K. Mechanisms of mesenchymal stromal cell immunomodulation. *Immunology and cell biology*. 2013;91:19-26.
  13. Mendez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, Lira SA, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. *Nature*. 2010;466:829-34.
  14. Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J, et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. *Leukemia*. 2007;21:1733-8.
  15. Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. *PloS one*. 2012;7:e47559.
  16. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. *Lancet (London, England)*. 2008;371:1579-86.
  17. Le Blanc K, Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*. 2005;11:321-34.

18. Lim JY, Cho BS, Min CK, Park G, Kim YJ, Chung NG, et al. Fluctuations in pathogenic CD4+ T-cell subsets in a murine sclerodermatous model of chronic graft-versus-host disease. *Immunological investigations*. 2014;43:41-53.
19. Oh MH, Oh SY, Yu J, Myers AC, Leonard WJ, Liu YJ, et al. IL-13 induces skin fibrosis in atopic dermatitis by thymic stromal lymphopoietin. *Journal of immunology (Baltimore, Md : 1950)*. 2011;186:7232-42.
20. Le Huu D, Kimura H, Date M, Hamaguchi Y, Hasegawa M, Hau KT, et al. Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease. *Journal of dermatological science*. 2014;74:214-21.
21. Goffin L, Seguin-Estevez Q, Alvarez M, Reith W, Chizzolini C. Transcriptional regulation of matrix metalloproteinase-1 and collagen 1A2 explains the anti-fibrotic effect exerted by proteasome inhibition in human dermal fibroblasts. *Arthritis research & therapy*. 2010;12:R73.
22. Pilcher BK, Dumin JA, Sudbeck BD, Krane SM, Welgus HG, Parks WC. The activity of collagenase-1 is required for keratinocyte migration on a type I collagen matrix. *The Journal of cell biology*. 1997;137:1445-57.
23. Gauldie J, Bonniaud P, Sime P, Ask K, Kolb M. TGF-beta, Smad3 and the process of progressive fibrosis. *Biochemical Society transactions*. 2007;35:661-4.
24. Fagone E, Conte E, Gili E, Fruciano M, Pistorio MP, Lo Furno D, et al. Resveratrol inhibits transforming growth factor-beta-induced proliferation and differentiation of ex vivo human lung fibroblasts into myofibroblasts through ERK/Akt inhibition and PTEN restoration. *Experimental lung research*. 2011;37:162-74.
25. New JY, Li B, Koh WP, Ng HK, Tan SY, Yap EH, et al. T cell infiltration and chemokine expression: relevance to the disease localization in murine graft-versus-host disease. *Bone marrow transplantation*. 2002;29:979-86.
26. Castor MG, Pinho V, Teixeira MM. The role of chemokines in mediating graft versus host disease: opportunities for novel therapeutics. *Frontiers in pharmacology*. 2012;3:23.
27. Lloyd CM, Rankin SM. Chemokines in allergic airway disease. *Current opinion in pharmacology*. 2003;3:443-8.
28. Matucci A, Vultaggio A, Maggi E, Kasujee I. Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question? *Respiratory research*. 2018;19:113.
29. Yagi H, Soto-Gutierrez A, Parekkadan B, Kitagawa Y, Tompkins RG, Kobayashi N, et al. Mesenchymal stem cells: Mechanisms of immunomodulation and homing. *Cell transplantation*. 2010;19:667-79.
30. Li J, Ezzelarab MB, Cooper DK. Do mesenchymal stem cells function across species barriers? Relevance for xenotransplantation. *Xenotransplantation*. 2012;19:273-85.
31. Jaffee BD, Claman HN. Chronic graft-versus-host disease (GVHD) as a model for scleroderma. I. Description of model systems. *Cellular immunology*. 1983;77:1-12.
32. Yamamoto T. Animal model of systemic sclerosis. *The Journal of dermatology*. 2010;37:26-41.

33. Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. *Annual review of immunology*. 2014;32:659-702.
34. Friedl P, Weigelin B. Interstitial leukocyte migration and immune function. *Nature immunology*. 2008;9:960-9.
35. Tomankova T, Kriegova E, Liu M. Chemokine receptors and their therapeutic opportunities in diseased lung: far beyond leukocyte trafficking. *American journal of physiology Lung cellular and molecular physiology*. 2015;308:L603-18.
36. Gonzalo JA, Pan Y, Lloyd CM, Jia GQ, Yu G, Dussault B, et al. Mouse monocyte-derived chemokine is involved in airway hyperreactivity and lung inflammation. *Journal of immunology (Baltimore, Md : 1950)*. 1999;163:403-11.
37. Kawasaki S, Takizawa H, Yoneyama H, Nakayama T, Fujisawa R, Izumizaki M, et al. Intervention of thymus and activation-regulated chemokine attenuates the development of allergic airway inflammation and hyperresponsiveness in mice. *Journal of immunology (Baltimore, Md : 1950)*. 2001;166:2055-62.
38. Bishop B, Lloyd CM. CC chemokine ligand 1 promotes recruitment of eosinophils but not Th2 cells during the development of allergic airways disease. *Journal of immunology (Baltimore, Md : 1950)*. 2003;170:4810-7.
39. Inngjerdingen M, Damaj B, Maghazachi AA. Human NK cells express CC chemokine receptors 4 and 8 and respond to thymus and activation-regulated chemokine, macrophage-derived chemokine, and I-309. *Journal of immunology (Baltimore, Md : 1950)*. 2000;164:4048-54.
40. Freeman CM, Chiu BC, Stolberg VR, Hu J, Zeibecoglou K, Lukacs NW, et al. CCR8 is expressed by antigen-elicited, IL-10-producing CD4+CD25+ T cells, which regulate Th2-mediated granuloma formation in mice. *Journal of immunology (Baltimore, Md : 1950)*. 2005;174:1962-70.
41. Inngjerdingen M, Damaj B, Maghazachi AA. Expression and regulation of chemokine receptors in human natural killer cells. *Blood*. 2001;97:367-75.
42. Soler D, Chapman TR, Poisson LR, Wang L, Cote-Sierra J, Ryan M, et al. CCR8 expression identifies CD4 memory T cells enriched for FOXP3+ regulatory and Th2 effector lymphocytes. *Journal of immunology (Baltimore, Md : 1950)*. 2006;177:6940-51.


## Figures



**Figure 1**


Human mesenchymal stem cells (hMSCs) attenuated the severity of skin sclerodermatous graft-versus-host disease (Scl-GVHD) but exacerbated pulmonary inflammation and fibrosis. (A): BALB/c mice transplanted with T cell-depleted bone marrow (TCD-BM) and spleen cells from B10.D2 mice had chronic dermatitis and an increased average skin score (Scl-GVHD). However, mice receiving human bone marrow (Scl-GVHD + hBM-MSCs) or adipose tissue (Scl-GVHD + hAD-MSCs)-derived hMSCs had markedly decreased chronic dermatitis and skin scores. BALB/c mice transplanted with cells from B10.D2 TCD-BM (Non GVHD control) did not show dermatitis or hair loss. (B): Paraffin-embedded tissue sections were stained with H&E (original magnification X100) for microscopic examination. (C): Masson's trichrome staining (original magnification X100) for assessing fibrosis. (D): mRNA expression of collagen 1  $\alpha$ 1, 1  $\alpha$ 2, 3  $\alpha$ 1 and soluble collagen were measured on day 14 (upper panel) and day 28 (lower panel) after transplantation. (E, F, G): Immunohistochemical staining of MMP1 (E), PTEN (F) and pSmad-3 (G) was

quantified on day 14 after transplantation. Original magnification, x100. Each value indicates mean  $\pm$  SEM of 4-9 mice per group. \* $P < 0.05$ ; \*\* $P < 0.01$ , \*\*\* $P < 0.001$ .




**Figure 2**

Migration of hMSCs into each organ and analysis of immune cell infiltration into skin and lung tissues. (A): PKH-26-labeled hAD-MSCs were injected into the tail vein on 3, 5 and 7 days after allo-HSCT. Skin, lung, liver, spleen and lymph node (LN) sections were analyzed by confocal microscopy for detection of PKH-26-positive cells (shown in red). Flow cytometric analyses were performed using skin and bronchoalveolar lavage fluid (BALF). (B, C): Frequency of CD4 T cells (B) and CD11b (C) cells 14, 28 and 42 days after transplantation. (D): Total BALF cell count 14 and 28 days after transplantation. Each value indicates mean  $\pm$  SEM of 4-9 mice per group. \* $P < 0.05$ ; \*\* $P < 0.01$ , \*\*\* $P < 0.001$ .




**Figure 3**

The different expression of chemokines after hMSC treatment in the skin and lungs. (A): Level of mRNA for CCL1, CCL2, CCL3, CCL5, CCL8, CCL17 and CCL22 in the skin and lungs 14 and 28 days after transplantation. (B): mRNA expression of CCR4, CCL17 and CCL22 receptor and CCR8, CCL1 receptor in the lungs 14 days after transplantation. Each value indicates mean  $\pm$  SEM of 4-9 mice per group. \*P<0.05; \*\*P<0.01, \*\*\*P<0.001.



**Figure 4**

CCL1 blockade attenuated the severity of lung histopathology score and fibrosis while maintaining protective effects against CGVHD in the skin. (A, B): Representative photomicrographs of histopathological changes from non-GVHD controls, Scl-GVHD, Scl-GVHD + hAD-MSCs +  $\alpha$ lgG, and Scl-GVHD + hAD-MSCs +  $\alpha$ CCL1 groups on day 20. Sections were stained with H&E (A) or Masson's trichrome (B). (C): CD3<sup>+</sup> T cell and CD68<sup>+</sup> macrophage infiltration of lung tissues were examined in each group. Each value indicates mean  $\pm$  SEM of 4-9 mice per group. \*P<0.05; \*\*P<0.01, \*\*\*P<0.001.



**Figure 5**

CCL1 blockade reduced Th2-related chemokine expression as well as eosinophil infiltration. (A): Level of mRNA for CCL1, CCL17 and CCL22 in the lungs and skin on day 20. (B): Eosinophil peroxidase (EPX) immunohistochemical staining was quantified on day 20. Original magnification, x200. (C): IgE production in the lungs and skin on day 20. Each value indicates mean  $\pm$  SEM of 4-9 mice per group. \* $P < 0.05$ ; \*\* $P < 0.01$ , \*\*\* $P < 0.001$ .

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementaldata.docx](#)